Guggenheim Maintains Buy on Pfizer, Lowers Price Target to $35

Benzinga Newsdesk www.benzinga.com Negative 54.6%

Neg 54.6% Neu 0% Pos 0%

Guggenheim analyst Vamil Divan maintains Pfizer (NYSE:PFE) with a Buy and lowers the price target from $36 to $35.

Comments

No comments yet. Be the first!